Pacific Shuanglin Bio-pharmacy , Ltd. EBIT

The latest EBIT for 000403.SZ is $260M as of September 2026. That compares with $620M in the prior-year period — down 57.6% year over year. That is below the Healthcare sector average of $2T. Investors often review this figure alongside Pacific Shuanglin Bio-pharmacy , Ltd.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, 000403.SZ's EBIT moved from $620M to $260M — a 57.6% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Pacific Shuanglin Bio-pharmacy , Ltd.'s operating scale or balance-sheet position.

Against Healthcare companies, 000403.SZ currently prints $260M for EBIT, while the sector average sits near $2T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Pacific Shuanglin Bio-pharmacy , Ltd.'s growth, margins, and balance sheet.

A EBIT figure of $260M for 000403.SZ is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $2T. Explore the charts below for those layers of context.

After noting 000403.SZ's EBIT ($260M), review year-over-year change from $620M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.